Aradigm

As a leader in pulmonary drug delivery, Aradigm is focused on improving the quality and cost-effectiveness of medical treatment by enabling patients to self-administer drugs—without needles or lengthy nebulizer treatments. To that end, we're developing novel drug delivery systems that exploit the lungs' natural ability to absorb and rapidly transfer molecules into the bloodstream.

Our development efforts center on the AERx® Pulmonary Drug Delivery System, which uses proprietary technology to create aerosols from liquid drug formulations and deliver these aerosols either locally to the lungs or systemically via the lungs. The AERx system is the only pulmonary delivery system that incorporates all the features deemed essential for accurate, reproducible pulmonary drug delivery. And because it is handheld and self-administered, the AERx system is potentially appropriate for both hospital and outpatient settings.

Prospects for pulmonary delivery include conventional pharmaceuticals as well as emerging biotechnology products that target a wide range of systemic diseases and disorders. Aradigm's systems—which can enhance the delivery and market competitiveness of existing and developmental-stage drugs—have the potential to play a significant role in any therapy where invasive delivery limits therapeutic benefits and/or patient compliance.